Land: Kanada
Sprache: Englisch
Quelle: Health Canada
CHLORHEXIDINE GLUCONATE
EURO-PHARM INTERNATIONAL CANADA INC
A01AB03
CHLORHEXIDINE
0.12%
MOUTHWASH
CHLORHEXIDINE GLUCONATE 0.12%
BUCCAL
500ML/4L
Prescription
MISCELLANEOUS ANTI-INFECTIVES
Active ingredient group (AIG) number: 0107629007; AHFS:
APPROVED
2017-04-05
1 PRODUCT MONOGRAPH PR EURO-CHLORHEXIDINE Chlorhexidine Gluconate Oral Rinse 0.12% w/v House Standard ANTIGINGIVITIS ORAL RINSE EURO-PHARM INTERNATIONAL CANADA INC. 9400 BOUL. LANGELIER MONTREAL, QUEBEC H1P 3H8 CONTROL NUMBER: 275418 DATE OF PREPARATION: APR 05, 2017 DATE OF REVISION: JUN 14, 2023 2 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 3 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 5 DRUG INTERACTIONS ................................................................................................... 5 DOSAGE AND ADMINISTRATION ............................................................................... 5 OVERDOSAGE ................................................................................................................. 6 ACTION AND CLINICAL PHARMACOLOGY ............................................................. 7 STORAGE AND STABILITY ........................................................................................... 8 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................. 8 PART II: SCIENTIFIC INFORMATION ................................................................................ 9 PHARMACEUTICAL INFORMATION ........................................................................... 9 CLINICAL TRIALS ......................................................................................................... 10 TOXICOLOGY .......................................................... Lesen Sie das vollständige Dokument